Results 251 to 260 of about 53,924 (268)
Some of the next articles are maybe not open access.
Intravenous Thrombolysis and Anti-thrombotics
2016Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has revolutionized acute ischemic stroke care in the last two decades. The NINDS stroke study was pivotal in this transformation and conclusively demonstrated meaningful clinical improvement when IV rtPA is administered in the first 3 h of symptom onset.
Rajsrinivas Parthasarathy +2 more
openaire +2 more sources
Intravenous Thrombolysis and Coronary Revascularization Rates
JAMA: The Journal of the American Medical Association, 1991To the Editor.— The impact of intravenous thrombolysis on the rates of short-term interventional procedures (cardiac catheterization, angioplasty, and bypass surgery) was addressed recently by Naylor and Jaglal 1 and, in an accompanying editorial, by Schlant.
openaire +3 more sources
Intravenous Thrombolysis for Acute Ischemic Stroke
Journal of Vascular and Interventional Radiology, 2004Intravenous recombinant tissue-type plasminogen activator (rtPA, alteplase) is the only drug approved for the treatment of acute ischemic stroke. It should be administered within 3 hours of stroke. There is additional evidence, however, that administration at later times, by means of other methods, is effective.
openaire +3 more sources
Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency
Journal of Stroke and Cerebrovascular Diseases, 2018No reports regarding the safety of thrombolysis in acute stroke patients with a G6PD deficiency have been published to date. Here we aimed to evaluate the safety of intravenous thrombolysis for G6PD-deficient stroke patients.We enrolled each patient with acute ischemic stroke who arrived in our stroke unit within the therapeutic window and received ...
Xiaoming Rong +7 more
openaire +3 more sources
Successful Intravenous Thrombolysis in a Stroke Patient With Hemiballism
The Neurologist, 2011Hemiballism (HB) is a relatively rare hyperkinetic disorder commonly caused by an acute stroke. Such patients usually receive symptomatic therapy with limited effect. We report the case of an acute stroke patient with HB who was successfully treated with intravenous recombinant tissue plasminogen activator (rtPA).A 67-year-old man with a history of ...
Dejana R. Jovanović +4 more
openaire +3 more sources
Off‐label intravenous thrombolysis in acute stroke
European Journal of Neurology, 2011Background and purpose: Therapy for stroke with intravenous tissue plasminogen activator (IV‐tPA) is hampered by tight licensing restrictions; some of them have been discussed in recent literature. We assessed the safety and effectiveness of off‐label IV‐tPA in the clinical settings.Methods: Retrospective analysis of all the patients treated with IV ...
M. Alonso de Leciñana +9 more
openaire +3 more sources
Intravenous Thrombolysis in Acute Ischemic Stroke
2018The only proven therapy for patients with acute ischemic stroke is early recanalization. The use of intravenous thrombolytic alteplase is the standard of care for patients presenting with ischemic stroke within the first 4.5 hours from symptom onset.
Waldo R. Guerrero +2 more
openaire +1 more source
Advantages and limits of intravenous thrombolysis
Journal of Molecular and Cellular Cardiology, 1988Rovelli F, Mauri F, De Biase Am
openaire +3 more sources